Clinical trials: Concentration
Psoriasis
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01119339
- Testing
- LAS 41004, LAS 41004 dosage 6, Reference
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Healthy
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in…
- Trial name
- NCT05517122
- Testing
- Nicotinamide (NAM), Nicotinamide Riboside (NR), Nicotinamide Mono Nucleotide (NMN)
- Where
- Switzerland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Embryo Transfer
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban
This multi-cohort phase I study is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytocin and to evaluate epelsiban (GSK557296) potential to reduce subendometrial contractractility induced by oxytocin…
- Trial name
- NCT02213029
- Testing
- Epelsiban, Oxytocin, Ortho-Cylcen (21)® tablet
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients…
- Trial name
- NCT00633997
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis
Mild Cognitive Impairment, Dementia
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many diseases. GSK239512 is a drug that binds to the Histamine 3 receptor (a protein) in the brain (receptor occupancy).
- Trial name
- NCT00474513
- Testing
- GSK239512
- Where
- Canada
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder
A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children
The purpose of this study is to compare the effectiveness (onset of effect, time to loss of effect, and overall efficacy) of methylphenidate given as an OROS® (methylphenidate HCl) formulation, compared to immediate-release…
- Trial name
- NCT00269789
- Testing
- Ritalin, OROS Methylphenidate HCl
- Sponsor
- Alza Corporation, DE, USA
Healthy
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators
The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
- Trial name
- NCT00703313
- Testing
- 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Santen Inc.
Healthy Volunteers
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
- Trial name
- NCT02828397
- Testing
- REGN2222
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Dry Eye Disease
BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED.
- Trial name
- BRIGHT (NCT07778888)
- Testing
- BL1107
- Volunteers
- 20 people
- Sponsor
- Bausch & Lomb Incorporated
PreDiabetes, Aging
Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration
Aging significantly impacts overall health and is a risk factor for developing diabetes. An estimated 50% of U.S. adults aged ≥65 years were reported to have prediabetes (defined as having a fasting glucose concentration of…
- Trial name
- NCT06445569
- Testing
- KH-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kalin Health, LLC
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Immunogenicity, Vaccine
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.
- Trial name
- NCT05372575
- Testing
- PCV13 PAC study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
- Trial name
- NCT00784654
- Testing
- Lisdexamfetamine dimesylate (LDX)
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 276 people
- Sponsor
- Shire
Healthy
Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274
The primary purpose of the study is to evaluate the effect of PF-04995274 on cerebrospinal fluid levels of soluble Amyloid precursor protein fragments and Amyloid beta fragments following single oral dose in healthy volunteers.
- Trial name
- NCT01193062
- Testing
- PF-04995274
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Memory, Learning
Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L
The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.
- Conditions
- Memory, Learning, Attention, Cognition
- Trial name
- REMEMBER-fX (NCT00527969)
- Testing
- HT1001 extract of Panax quinquefolius L
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction, Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of oral contraceptive (Microgynon® 30) in the blood of healthy female subjects.
- Trial name
- NCT01276262
- Testing
- fostamatinib, Microgynon® 30 (Oral contraceptive)
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, Healthy Volunteers
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib…
- Conditions
- Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone
- Trial name
- NCT01309854
- Testing
- fostamatinib, pioglitazone
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.